explore -WSS

explore

author：leisure time 2025-10-02 22:57:46 - browse：2

A display of TVs against an orange background. -- health policy coverage from STAT — Adobe

WASHINGTON — Government regulators may soon decide whether to crack down on distracting visuals in television drug commercials or require subtitles about side effects, a regulation that’s been 13 years in the making.

White House budget experts are reviewing changes to the regulation of broadcast drug advertisements that the Food and Drug Administration proposed in 2010, according to the Office of Management and Budget website. That proposal aimed to make commercials present drug risks in a manner that consumers notice and understand.

Drug ads have long been controversial. Aside from New Zealand, the United States is the only country that allows drug makers to advertise to consumers. Critics of drug ads say they pose consumer safety concerns by bombarding the public with promotions that distract viewers from potential side effects. Drug companies say commercials spark conversations between patients and doctors that promote clinically beneficial prescribing.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

focus

knowledge

WSS

FTC loses bid to block Novant's North Carolina hospital merger

David Sabatini, ex

Surge of respiratory disease in China has likely explanation

Hospitals look to new technology to keep health care workers safe

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

Data don't support strong claims for Covid

knowledge

explore

knowledge

Alkermes shareholders re

Does good food count as health care? Study aims to find out

Wildfire smoke exposes gaps in outdoor worker protections

Structure Therapeutics oral GLP

Affirmative action in medical school literally saved lives

UnitedHealth CEO's Medicaid comments send insurer stocks diving

Medical records are filled with copy

FDA's Woodcock to retire early next year

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

Wikipedia

Structure Therapeutics oral GLP

ASCO Daily Recap: CAR

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

In key trial, Verve's treatment lowers cholesterol levels in patients

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

STAT wants to know your pick for a great summer read or listen

focus

knowledge

Wikipedia

entertainment